Publicou 6 edições por ano
ISSN Imprimir: 1045-4403
ISSN On-line: 2162-6502
Indexed in
AML1-ETOMediated Erythroid Inhibition: New Paradigms for Differentiation Blockade by a Leukemic Fusion Protein
RESUMO
The chromosomal translocation t(8;21), generating the AML1-ETO fusion protein, is frequently associated with French-American-British (FAB) type M2 acute myeloid leukemia (AML). t(8;21) fuses the runt domain from the hematopoietic transcription factor RUNX1 with almost the entire transcriptional repressor ETO. AML1-ETO inhibits normal definitive hematopoiesis and blocks erythroid differentiation. Several mechanistic models for the role of AML1-ETO in leukemia development have emerged over the last decade. Most of these models have emphasized the capacity of the fusion protein to redirect repressive cofactors, such as histone deacetylases (HDACs) and DNA methyltransferases (DNMTs), to RUNX target genes, thereby reversing the hematopoietic transcriptional program activated by wild-type RUNX1a phenomenon referred to collectively in this review as the "classical" corepressor model. Because erythropoiesis occurs in a RUNX-independent manner, this dominant-negative "classical" model cannot explain the prominent repression of red-cell development by AML1-ETO. This review will consider the clinical and mechanistic significance of erythroid inhibition by AML1-ETO. Additional models to account for this mysterious oncogenic function are proposed.
-
Steele MacGregor, Narendran Aru, Mechanisms of defective erythropoiesis and anemia in pediatric acute lymphoblastic leukemia (ALL), Annals of Hematology, 91, 10, 2012. Crossref
-
Stuardo Marcela, Martinez Milka, Hidalgo Karla, Montecino Martin, Javed Amjad, Lian Jane B., Stein Gary S., Stein Janet L., Gutiérrez Soraya E., Altered chromatin modifications inAML1/RUNX1breakpoint regions involved in (8;21) translocation, Journal of Cellular Physiology, 218, 2, 2009. Crossref
-
Ocio Enrique M., San Miguel Jesús F., The DAC system and associations with multiple myeloma, Investigational New Drugs, 28, S1, 2010. Crossref
-
Lohrum Marion, Stunnenberg Hendrik G., Logie Colin, The new frontier in cancer research: Deciphering cancer epigenetics, The International Journal of Biochemistry & Cell Biology, 39, 7-8, 2007. Crossref
-
Wamstad Joseph Alan, Corcoran Connie Marie, Keating Anne Marjorie, Bardwell Vivian J., Najbauer Joseph, Role of the Transcriptional Corepressor Bcor in Embryonic Stem Cell Differentiation and Early Embryonic Development, PLoS ONE, 3, 7, 2008. Crossref
-
Murakami Takashi, Transcriptional Modulation Using Histone Deacetylase Inhibitors for Cancer Immunotherapy, in Experimental and Applied Immunotherapy, 2011. Crossref
-
Peterson Luke F., Boyapati Anita, Ahn Eun-Young, Biggs Joseph R., Okumura Akiko Joo, Lo Miao-Chia, Yan Ming, Zhang Dong-Er, Acute myeloid leukemia with the 8q22;21q22 translocation: secondary mutational events and alternative t(8;21) transcripts, Blood, 110, 3, 2007. Crossref
-
Zangari Maurizio, Berno Tamara, Zhan Fenghuang, Histone deacetylase inhibitors, in Current & Emerging Therapeutics for Multiple Myeloma, 2013. Crossref
-
Dokmanovic Milos, Clarke Cathy, Marks Paul A., Histone Deacetylase Inhibitors: Overview and Perspectives, Molecular Cancer Research, 5, 10, 2007. Crossref
-
Inthal Andrea, Krapf Gerd, Beck Dominik, Joas Ruth, Kauer Max O., Orel Lukas, Fuka Gerhard, Mann Georg, Panzer-Grümayer E. Renate, Role of the Erythropoietin Receptor in ETV6/RUNX1-Positive Acute Lymphoblastic Leukemia, Clinical Cancer Research, 14, 22, 2008. Crossref
-
Plevin Michael J., Zhang Jinsong, Guo Chun, Roeder Robert G., Ikura Mitsuhiko, The acute myeloid leukemia fusion protein AML1-ETO targets E proteins via a paired amphipathic helix-like TBP-associated factor homology domain, Proceedings of the National Academy of Sciences, 103, 27, 2006. Crossref